Literature DB >> 8810876

Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition.

T Müller1, P Engels, J R Fozard.   

Abstract

The 'famille nombreuse' of cyclic nucleotide phosphodiesterases, responsible for degrading the ubiquitous second messenger molecules, cAMP and cGMP, maintains its place as a major focus of interest for many research laboratories in both academia and industry. The increase in knowledge of the primary sequences, plus the availability of selective inhibitors, are rapidly improving our insight into the structure, regulation and function of these pivotal enzymes of cellular homeostasis. Here, Thomas Müller, Peter Engels and John Fozard focus on family 4 of the phosphodiesterases, which is of particular interest owing to both the number of genes (and splice variants) and the emergence of selective inhibitors, which are enabling the functional significance of these enzymes to be defined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8810876     DOI: 10.1016/0165-6147(96)10035-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  15 in total

Review 1.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes.

Authors:  Elizabeth Borysiewicz; Daniel Fil; Daniel Dlaboga; James M O'Donnell; Gregory W Konat
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

Review 3.  New therapies for chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

4.  Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats.

Authors:  N Vanattou-Saïfoudine; R McNamara; A Harkin
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Histamine H(3) receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves.

Authors:  C Blandizzi; M Tognetti; R Colucci; M Del Tacca
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 6.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

7.  Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.

Authors:  K Murata; T Sudo; M Kameyama; H Fukuoka; M Muka; Y Doki; Y Sasaki; O Ishikawa; Y Kimura; S Imaoka
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 8.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

9.  Modulation of the cAMP signaling pathway after traumatic brain injury.

Authors:  Coleen M Atkins; Anthony A Oliva; Ofelia F Alonso; Damien D Pearse; Helen M Bramlett; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2007-08-29       Impact factor: 5.330

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.